NasdaqGM - Nasdaq Real Time Price USD

MediWound Ltd. (MDWD)

13.30 -0.56 (-4.04%)

At close: October 30 at 4:00:01 PM EDT

13.30 -0.03 (-0.23%)

After hours: October 30 at 4:00:05 PM EDT

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Name	Title	Pay	Exercised	Year Born
Mr. Ofer Gonen B.Sc.	Chief Executive Officer	834k	--	1973
Ms. Hani Luxenburg	Chief Financial Officer	420k	--	1974
Dr. Shmulik Hess Ph.D.	COO & Chief Commercial Officer	426k	--	1974
Mr. Yaron Meyer Adv.	Executive VP, General Counsel & Corporate Secretary	337k	--	1979
Dr. Ety Klinger MBA, Ph.D.	Chief Medical Officer	428k	--	1962
Dr. Liron Gal	Vice President of Manufacturing Science & Technology	--	--	--
Mr. Barry J. Wolfenson	Executive Vice President of Strategy & Corporate Development	--	--	1967
Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc.	Senior Vice President of Global Medical Affairs	--	--	1951

42 Hayarkon Street

Yavne, 8122745

Israel

972 7 797 14100 https://www.mediwound.com

Sector:: Healthcare
Industry:
Full Time Employees:: 121

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

MediWound Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

November 12, 2026 at 12:30 PM UTC

MediWound Ltd. Earnings Date

August 13, 2026 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

See Full Filing

May 27, 2026 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

See Full Filing

May 6, 2026 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

See Full Filing

April 2, 2026 at 12:00 AM UTC